Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI coach may soothe radiation skin burns in breast cancer patients

NCT ID NCT07649902

Symptom relief Sponsor: Ataturk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence-powered digital education program can reduce the severity of radiodermatitis (skin irritation from radiation) and improve quality of life in women with breast cancer. 38 patients will be randomly assigned to either receive the AI program or standard care. The program includes modules on skin care, symptom management, and emotional support, with personalized reminders. Researchers will measure skin reactions weekly and quality of life before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-powered digital education program
What this could lead to
If it works, this could offer a simple, non-drug way to reduce skin side effects and improve well-being for breast cancer patients during radiotherapy.
What could go wrong
This is a small, early-stage trial with only 38 participants, so results may not apply to everyone. The program's success depends on patient engagement and internet access.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 38 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 years or older diagnosed with primary breast cancer who have completed surgical treatment and are scheduled to receive adjuvant radiotherapy. * Patients who will receive radiotherapy for the first time. * Patients whose general health condition is suitable for participation in the study and follow-up assessments. * Patients who are able to read, understand, and communicate in Turkish. * Patients who have access to the internet and are able to use a smartphone, tablet, or computer to access the digital education program. * Patients who voluntarily agree to participate in the study and provide written informed consent. Exclusion Criteria: * Previous radiotherapy to the same treatment area. * Presence of an active infection, open wound, or severe dermatological disease within the radiation treatment field. * History of a chronic skin condition that may affect radiation-induced skin reactions. * Cognitive or psychiatric conditions that may prevent participants from following the educational program or complying with the study procedures and data collection process.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm radiodermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Radiodermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.